Tallac Therapeutics offers next generation immunotherapies for cancer patients.
Tallac Therapeutics has raised $5.0M in total funding. The most recent round was Debt Financing. The last funding was announced in August 2023.
Tallac Therapeutics's investors include Matrix Partners China, venBio Partners, Lightstone Ventures, Horizon Technology Finance, MRL Ventures Fund.
Tallac Therapeutics is headquartered in Burlingame, United States.
Tallac Therapeutics offers next generation immunotherapies for cancer patients.
Tallac Therapeutics is at the Debt Financing stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Tallac Therapeutics — Funding & Investors." VCBacked, August 2, 2023, https://www.vcbacked.co/company/tallac-therapeutics. Accessed September 30, 2026.
VCBacked. (2023). Tallac Therapeutics — Funding & Investors. Retrieved September 30, 2026, from https://www.vcbacked.co/company/tallac-therapeutics
{{cite web |title=Tallac Therapeutics — Funding & Investors |url=https://www.vcbacked.co/company/tallac-therapeutics |website=VCBacked |access-date=September 30, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated